Treatment of human papillomavirus with peg-interferon alfa-2b and ribavirin

Treatment of human papillomavirus with peg-interferon alfa-2b and ribavirin

We reported one case of human immunodeficiency virus and hepatitis C virus co-infected patient who presented a significant improvement of human papillomavirus (HPV) lesions during the treatment of chronic hepatitis using peg-interferon alfa-2b and ribavirin.

Bibliographic Details
Main Authors:	M.H.P. Pavan, P.E.N.F. Velho, A.G. Vigani, F.L. Gonçalves Jr., F.H. Aoki
Format:	Article
Language:	English
Published:	Elsevier
Series:	Brazilian Journal of Infectious Diseases
Subjects:	Hepatitis C human immunodeficiency virus human papillomavirus pegylated-interferon ribavirin
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702007000300017&lng=en&tlng=en

Similar Items

Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon – Ribavirin in daily practice
by: Ezequiel Ridruejo, MD., et al.
Published: (2010-01-01)

Psoriasis induced by Interferon alfa-2a and ribavirin in a patient followed for hepatitis C
by: N. Amraoui, et al.
Published: (2015-07-01)

Characteristics of hepatitis C treatment with pegylated interferons and ribavirin
by: Ricardo Jiménez-Méndez, et al.
Published: (2010-01-01)

Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan
by: Jung-An Lin, et al.
Published: (2014-10-01)

Pityriasis Rosea Associated with Pegylated Interferon Alfa and Ribavirin Treatment in a Patient with Chronic Hepatitis C
by: Rahmet Güner, et al.
Published: (2013-06-01)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
by: Janine Hartl, et al.
Published: (2012-07-01)

Pegylated Interferon (Alone or With Ribavirin) for Chronic Hepatitis C in Haemodialysis Population
by: Mario Espinosa, et al.
Published: (2015-05-01)

Response factors to pegylated interferon-alfa/ribavirin treatment in chronic hepatitis C patients genotype 1b
by: Jovanović-Ćupić Snežana, et al.
Published: (2014-01-01)

Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting
by: Sergio Sabbatani, et al.

Autoimmune thyroid diseases in patients with chronic hepatitis C treated by pegylated interferon-alpha and ribavirin: A prospective study
by: Ružić Maja, et al.
Published: (2017-01-01)

Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients
by: Chen Z, et al.
Published: (2017-08-01)

EFFICACY AND SAFETY OF THE COMBINATION OF RIBAVIRIN AND PEGYLATED INTERFERON ALFA-2A IN PATIENTS WITH CHRONIC HEPATITIS C: THE RESULTS OF TWO MULTICENTER, PROSPECTIVE, OPEN, NON-COMPARATIVE CLINICAL TRIALS
by: K. V. Zhdanov, et al.
Published: (2018-01-01)

The interleukin 28B gene polymorphism, rs8099917, in patients with chronic hepatitis C and response to the treatment with pegylated interferon and ribavirin
by: Hamid Kalantari, et al.
Published: (2019-01-01)

The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients
by: Nishikawa Hiroki, et al.
Published: (2012-03-01)

Toll-like receptors 7 and 8 mRNA in monocytes of Egyptian children with chronic hepatitis C infection genotype 4 as predictor to “response” interferon and ribavirin treatment
by: Mohammed A. Khedr, et al.
Published: (2016-03-01)

Efficacy of combined antiviral therapy with pegylated interferon α-2a and ribavirin for chronic hepatitis C infection in intravenous drug users
by: Ružić Maja, et al.
Published: (2010-01-01)

Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort
by: Ta-Wei Liu, et al.
Published: (2018-01-01)

A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C
by: Byung Chul You, et al.
Published: (2012-09-01)

Porphyria cutanea tarda in an HCV-positive liver transplant patient: a case report
by: Adriano M. Pellicelli, M.D., et al.
Published: (2012-11-01)

The Sustained Virologic Response and Adverse Effects of Peg Interferon Alfa and Ribavirin in the Treatment of Patients with Chronic Hepatitis C: A Study from Iran
by: Simindokht Shoaei, et al.
Published: (2017-10-01)

Antiviral/immunomodulatory combination therapy: Pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection
by: Delić Dragan, et al.
Published: (2012-01-01)

An open, non-controlled clinical study to assess the efficacy and safety of the recombinant human alpha 2b pegylated interferon PEG-Heberon® plus ribavirin for the treatment of chronic hepatitis C virus infection in Cuban patients
by: Marlen I Castellanos-Fernández, et al.

Interleukin-28B (rs12979860) gene variation and treatment outcome after peginterferon plus ribavirin therapy in patients with genotype 1 of hepatitis C virus
by: Hamid Kalantari, et al.
Published: (2014-01-01)

Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy
by: E. Parise, et al.

Effect of Pegylated Interferon on Non-Responders and Relapsers with Interferon
by: Hisham O. Akbar, et al.
Published: (2002-04-01)

Addition of pentoxifylline to pegylated interferon-alpha-2a and ribavirin improves sustained virological response to chronic hepatitis C virus: a randomized clinical trial
by: Miguel Ángel Jiménez-Luévano, et al.
Published: (2013-03-01)

Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial
by: Lin YC, et al.
Published: (2019-04-01)

Peg-Interferon Alfa 2-b Related Cellulitis in a 40 Years Man
by: Shahnaaz Sali, et al.
Published: (2016-01-01)

Efficacy of triple therapy with thymalfasin, peginterferon α-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders
by: Jorge L. Poo, et al.
Published: (2008-10-01)

Extended treatment with interferon and ribavirin in a hemodialysis patient with chronic hepatitis C
by: Aline Gonzalez Vigani, et al.

Increase of ribavirin dose improves sustained virological response in HCV-genotype 1 patients with a partial response to peg-interferon and ribavirin
by: Fabio Conti, et al.
Published: (2014-03-01)

New approaches and therapeutic modalities for the treatment of patients with chronic hepatitis C
by: Markus Cornberg, et al.
Published: (2005-07-01)

The expirience of IDEAL
by: E. Z. Burnevich
Published: (2014-09-01)

Telaprevir: New possibilities for antiviral treatment in patients with chronic hepatitis C
by: I G Nikitin, et al.
Published: (2012-11-01)

Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
by: Sundaram V, et al.
Published: (2016-06-01)

Dynamics of hepatitis C virus infection
by: Stefan Zeuzem, M.D., et al.
Published: (2002-04-01)

Ribavirin in acute viral hepatitis.
by: Tilve G, et al.
Published: (1991-07-01)

Treatment of hepatitis C in liver transplant recipients in the Moscow Center for Liver Transplantation within 10 years
by: M. Sh. Khubutia, et al.
Published: (2016-01-01)

A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-naïve chronic hepatitis C patients in Taiwan
by: Pei-Chien Tsai, et al.
Published: (2017-01-01)

Very-Low-Dose Pegylated Interferon α2a Plus Ribavirin Therapy for Advanced Liver Cirrhosis Type C: A Possible Therapeutic Alternative without Splenic Intervention
by: Shogo Ohkoshi, et al.
Published: (2010-07-01)

Cannot write session to /tmp/vufind_sessions/sess_i6d05dqoppus7vqlvbjjage30d